Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL354962 | 1.00 | OPRK1 (0.49) | OPRK1HRH3ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL1725336 | 1.00 | OPRK1 (0.49) | OPRK1HRH3ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL354878 | 0.99 | OPRK1 (0.50) | OPRK1HRH3ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL354877 | 0.99 | OPRK1 (0.50) | OPRK1HRH3ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL4776245 | 0.93 | OPRK1 (0.53) | OPRK1ALDH1A1PLAUKDM4EDRD2 | |
| SCHEMBL1725563 | 0.88 | HRH3 (0.53) | HRH3ALDH1A1POLBSMN1; SMN2HTT | |
| SCHEMBL5634205 | 0.87 | LMNA (0.49) | OPRK1PLAUPRMT6DRD2DRD3 | |
| SCHEMBL5633241 | 0.87 | OPRK1 (0.48) | OPRK1HRH3ALDH1A1PLAUDRD2 | |
| SCHEMBL5633787 | 0.86 | OPRK1 (0.50) | OPRK1HRH3ALDH1A1POLBPLAU | |
| SCHEMBL4780284 | 0.86 | OPRK1 (0.47) | OPRK1HRH3PLAUDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304065-B2 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-04 | — | — | US | claimed |
| EP-1667958-A2 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2005033063-A2 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2005-04-14 | — | — | WO | claimed |
| US-20050075324-A1 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2005-04-07 | — | — | US | claimed |
| EP-2188273-B1 | SUBSTITUTED TETRA HYDRO NAPHTHALINES, METHOD FOR THEIR MANUFACTURE AND THEIR USE AS DRUGS | SANOFI SA (FR) | 2014-10-22 | — | — | EP | disclosed |
| US-8841290-B2 | Substituted tetrahydronaphthalenes, method for the production thereof, and use thereof as drugs | SANOFI (FR) | 2014-09-23 | — | — | US | disclosed |
| US-20140088077-A1 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | SANOFI (FR) | 2014-03-27 | — | — | US | disclosed |
| US-8609731-B2 | Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments | SANOFI (FR) | 2013-12-17 | — | — | US | disclosed |
| US-20120015936-A1 | SUBSTITUTED TETRAHYDRONAPHTHALENES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI (FR) | 2012-01-19 | — | — | US | disclosed |
| EP-2396300-A1 | NEW SUBSTITUTED TETRAHYDRONAPTHALENES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI (FR) | 2011-12-21 | — | — | EP | disclosed |
| US-20100249097-A1 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| WO-2010092153-A1 | NEW SUBSTITUTED TETRAHYDRONAPTHALENES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | WO | disclosed |
| EP-2188273-A2 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | Sanofi-Aventis (FR) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009021740-A2 | SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | SANOFIS-AVENTIS (FR) | 2009-02-19 | — | — | WO | disclosed |
| WO-2008001160-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| US-7304065-B2 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-20060247239-A1 | Melanin concentrating hormone antagonists | HU XIUFENG E | 2006-11-02 | — | — | US | disclosed |
| US-20050075324-A1 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088077-A1 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | DHPS, CYP11B2, CYP11B1 | OPRK1 912/4885HRH3 561/4885ALDH1A1 863/4885 |
| US-20050075324-A1 | Melanin concentrating hormone antagonists | MCHR1, MCHR2, MC1R | OPRK1 90/4885HRH3 781/4885ALDH1A1 3383/4885 |
| US-20060247239-A1 | Melanin concentrating hormone antagonists | MCHR1, MCHR2, MC1R | OPRK1 90/4885HRH3 781/4885ALDH1A1 3383/4885 |
| US-20100249097-A1 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | DHPS, CYP11B2, CYP11B1 | OPRK1 912/4885HRH3 561/4885ALDH1A1 863/4885 |
| US-20120015936-A1 | SUBSTITUTED TETRAHYDRONAPHTHALENES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | PAH, MCHR1, DHPS | OPRK1 147/4885HRH3 350/4885ALDH1A1 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.